People need healthcare products and services regardless of what's happening with the economy. Which healthcare stocks could ...

Travere Therapeutics stock did suffer a bit of setback last week as the FDA moved back the anticipated decision date on a ...

Suzhou Sanegene Bio Inc. has gained clinical trial approval in China for SGB-3383 for the treatment of complement-mediated kidney diseases, including IgA nephropathy, C3 glomerulopathy, immune complex ...

Moderator Sagar Nigwekar, MD, of Massachusetts General Hospital in Boston, is joined by Edgar Lerma, MD, of the University of ...

Panelists discuss how disease-modifying therapies for immunoglobulin A (IgA) nephropathy, though initially more expensive ...

Panelists discuss how early diagnosis of immunoglobulin A (IgA) nephropathy enables timely interventions that can ...

Over a 35-year journey with a rare kidney disease, Ginger Murphy has become an advocate for her own health and welcomes the ...

From Kilkenny hurling to dialysis, his mindset remains strong, and now while on the transplant list for a kidney he is ...

Travere Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for traditional approval of FILSPARI (sparsentan) ...

Vera Therapeutics faces a pivotal moment with Phase 3 data expected soon. Depending on the result, the stock may spike or ...

Research and Development (R&D) expenses: R&D expenses totaled $20.0 million for the first quarter of 2025. These expenses ...

Gov. Mike DeWine and Lt. Gov. Jim Tressel proclaimed May 14 as IgA Nephropathy Day. Meanwhile, Katie Strange continue to ...